Regenxbio Announces FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II
Aug 18 (Reuters) - Regenxbio Inc RGNX.O:
REGENXBIO ANNOUNCES FDA REVIEW EXTENSION OF BLA FOR RGX-121 TO TREAT PATIENTS WITH MPS II
REGENXBIO INC - PDUFA DATE EXTENDED TO FEBRUARY 8, 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.